Women’s health equity funding hits new high, drawing $1.55B in 2025
Women’s health companies raised a record $1.55 billion in disclosed equity in 2025, up 41% year over year. Funding became less concentrated, suggesting capital spread across more companies and categories, according to a new report from W Group.
In 2025, women's health companies attracted a record $1.55 billion in disclosed equity investments, marking a 41% increase from $1.1 billion in the previous year, according to a report by W Group. The report, the first of its kind, tracked over 500 funding stories and 164 equity rounds across more than 500 companies in 164 countries.
The sector reached its largest-ever scale, with 85 companies raising equity in 2025, surpassing the previous record. Ten rounds achieved $50 million or more, a significant increase from 2024. This marks the shift from a few breakout companies to a functioning, broad-based investment ecosystem. The report indicates that 2026 will be the era of scale for women's health.
The funding has become more diversified, with capital distributed across more companies, categories, and countries than ever before. The top three rounds in 2024 accounted for 41% of the disclosed capital, but this share fell to 32% in 2025 as funding to other companies grew. The remaining 76 deals accounted for approximately $675 million.
The lower concentration in the top rounds meant that the remaining 83 deals shared about $1.05 billion. Categories such as oncology, fertility, maternal care, and menopause received significant investments, with $57 million and $8 million allocated to endometriosis and women's bone health, respectively. Despite these efforts, women's cardiovascular health and autoimmune diseases remained largely unfunded.
The geographic range of investments expanded, with Germany, Austria, Switzerland, Israel, and the U.K. joining the U.S. in terms of company profiles. Additionally, new players emerged in the investment landscape, including Nina Capital, Bread & Butter Ventures, and GG Ventures, as well as celebrity investors like Meghan Markle and Emma Watson.
However, a significant structural risk identified in the report is the series A bottleneck, where only around 20 to 25 companies reach the series A stage out of 35 to 40 companies raising pre-seed and seed rounds each year. The report emphasizes that while women's health has reached unprecedented levels of funding, the real challenge lies in ensuring that growth continues and exit pathways are ready for these companies in 2026.
Written by urgent.news from Fierce Healthcare's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
